Search

In order to meet consumer demands for electric transportation, the energy density of lithium-ion batteries (LIB) must be improved. Therefore, a trend to increase the overall size of the individual cell and to decrease the share of inactive materials is needed. The process of electrolyte filling involves the injection of electrolyte liquid into the cell, as well as the absorption of the electrolyte into the pores of the electrodes and the separator, which is known as wetting. The trend towards larger-format LIB challenges the electrolyte filling due to an increase in wetting distance for the electrolyte as well as a decrease in the void volume of the cell. The optimization of the process via numerical simulation promises to reduce costs and ensure quality during battery production. The two models developed in this study are based on a commercial computational fluid dynamics (CFD) program to study the effect of process parameters, such as pressure and temperature, on the filling process. The results were verified with neutron radiography images of the dosing process and a feasibility study for a wetting simulation is shown. For all simulations, specific recommendations are provided to set up the electrolyte filling process, based on which factors generate the greatest improvement. [ABSTRACT FROM AUTHOR]

• This study assesses detailed first-hand data and therefore provides a very high data quality. • Detailed interviews, abstraction of medical records and laboratory analyses were combined to obtain comprehensive data sets. • More than half of the cases (58 %) were not vaccinated at all, compared to 11 % of the controls. • The vaccine effictiveness to prevent severe disease in the Delta wave was 89 % overall for two doses and 98 % for three doses. We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE was 89 % (95 % CI 84–93 %) overall, 79 % in patients with more than two comorbidities and 77 % in adults aged 60–75 years. A third dose increased the VE to more than 93 % in all patient-subgroups. [ABSTRACT FROM AUTHOR]

Before the international spread of monkeypox in May 2022, PCR kits for the detection of orthopoxviruses, and specifically monkeypox virus, were rarely available. Here we describe the evaluation of 11 recently developed commercially available PCR kits for the detection of monkeypox virus DNA. All tested kits are currently intended for research use only and clinical performance still needs to be assessed in more detail, but all were suitable for diagnostics of monkeypox virus, with variations in specificity rather than sensitivity.